Dr Reddy's Laboratories' US arm is recalling over 35,000 tubes of Nystatin and Triamcinolone Acetonide cream on account of failed stability specifications, USFDA said.
As per the US health regulator's Enforcement Report, Dr Reddy's Labs Inc is recalling 35,020 tubes of Nystatin and Triamcinolone Acetonide Cream, USP, 1,00,000 units/gm and 1 mg/gm from the American market.
The recall is on account of "failed stability specifications - an out of specification result was observed for the test parameter : composition of Nystatin during stability testing," it added.
The cream is used for treatment of cutaneous candidiasis, a skin infection.
The voluntary ongoing nationwide recall is a class II recall, United States Food and Drug Administration (USFDA)said.
As per USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
